Home
All Resources

Preparing for, Surviving and Thriving in a Consolidating Pharmaceutical Industry

Written by Samantha Schwab

Updated: Apr 11, 2021

Authors
More from the author

By Jamie Weissglass

Preparing for, Surviving and Thriving in a Consolidating Pharmaceutical Industry, Screenshot, Front Page

The pharmaceutical industry is experiencing heightened merger and acquisition activity, due in large part to rising competition, increasing regulatory challenges and expiring patents’ periods of exclusivity. In 2018, the industry saw 248 mergers worth approximately $198 billion; one law firm predicts that the value of transactions will soar to $331 billion in 2019.

In the course of these transactions, many pharmaceutical companies have encountered information governance challenges that they did not anticipate—or budget for—prior to the merger. As they begin to assess the disparate data source landscapes in an effort to unify their systems, issues in their document retention, preservation and retrieval become readily apparent, requiring a substantial amount of time and monetary investment to resolve—resources that are typically scarce after a transaction closes. This generally means that the necessitated data mapping, remediation and integration endeavors are deprioritized, leaving these combined organizations even more exposed in the event of litigation or a regulatory or compliance investigation.

This white paper takes a closer look at the status of mergers and acquisitions in the pharmaceutical industry, the challenges that these transactions exacerbate for the combined companies and solutions for mitigating those risks.

Read the Full Whitepaper.

By Jamie Weissglass

Preparing for, Surviving and Thriving in a Consolidating Pharmaceutical Industry, Screenshot, Front Page

The pharmaceutical industry is experiencing heightened merger and acquisition activity, due in large part to rising competition, increasing regulatory challenges and expiring patents’ periods of exclusivity. In 2018, the industry saw 248 mergers worth approximately $198 billion; one law firm predicts that the value of transactions will soar to $331 billion in 2019.

In the course of these transactions, many pharmaceutical companies have encountered information governance challenges that they did not anticipate—or budget for—prior to the merger. As they begin to assess the disparate data source landscapes in an effort to unify their systems, issues in their document retention, preservation and retrieval become readily apparent, requiring a substantial amount of time and monetary investment to resolve—resources that are typically scarce after a transaction closes. This generally means that the necessitated data mapping, remediation and integration endeavors are deprioritized, leaving these combined organizations even more exposed in the event of litigation or a regulatory or compliance investigation.

This white paper takes a closer look at the status of mergers and acquisitions in the pharmaceutical industry, the challenges that these transactions exacerbate for the combined companies and solutions for mitigating those risks.

Read the Full Whitepaper.

Fill out the form below to download the complete insight.

Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Sign up for Consilio updates

不管怎么样,我们都很友善,祝你好运。在悲惨的情绪中,人们对各种各样的恐惧感情有独钟的感觉。
谢谢!您提交的内容已收到!
单击 “注册” 即表示您确认您同意我们的 隐私政策
哎哟!提交表单时出了点问题。